Abbvie ABBV

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$4.75 (+2.25%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of Abbvie (ABBV)
    AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $214.29

    • Market Cap

      $378.30 Billion

    • Price-Earnings Ratio

      74.67

    • Total Outstanding Shares

      1.77 Billion Shares

    • Total Employees

      50,000

    • Dividend

      $1.64 Per Share Quarterly

    • IPO Date

      December 10, 2012

    • SIC Description

      Pharmaceutical Preparations

    • Primary Exchange

      New York Stock Exchange

    • Type

      Common Stock

    • Headquarters

      1 north waukegan road, North chicago, IL, 60064

    • Homepage

      https://www.abbvie.com

    Historical Stock Splits

    Execution DateSplit Amount
    No Historical Stock Splits

    Cash Flow Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities$-2.80 Billion
    Net Cash Flow$-6.03 Billion
    Net Cash Flow From Operating Activities, Continuing$16.51 Billion
    Net Cash Flow From Investing Activities$-19.75 Billion
    Net Cash Flow From Operating Activities$16.51 Billion
    Net Cash Flow From Investing Activities, Continuing$-19.75 Billion

    Income Statement

    October 1, 2023 to September 30, 2024
    MetricValue
    Cost Of Revenue$18.21 Billion
    Benefits Costs and Expenses$35.25 Billion
    Income/Loss From Continuing Operations Before Tax$20.29 Billion
    Selling, General, and Administrative Expenses$14.09 Billion
    Preferred Stock Dividends And Other Adjustments$30 Million
    Gross Profit$37.32 Billion

    Comprehensive Income

    October 1, 2023 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$5.10 Billion
    Other Comprehensive Income/Loss$-29 Million
    Comprehensive Income/Loss Attributable To Parent$5.09 Billion
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$9 Million

    Balance Sheet

    October 1, 2023 to September 30, 2024
    MetricValue
    Noncurrent Assets$115.64 Billion
    Fixed Assets$5.14 Billion
    Other Non-current Assets$43.85 Billion
    Liabilities$137.35 Billion
    Current Liabilities$43.06 Billion
    Intangible Assets$66.65 Billion

    Historical Dividends

    Current dividend: $1.64 Per Share Quarterly
    Announcement DatePayment DateRecord DateAmountFrequency
    Feb 13, 2025May 15, 2025Apr 15, 2025$1.64Quarterly
    Oct 30, 2024Feb 14, 2025Jan 15, 2025$1.64Quarterly
    Sep 6, 2024Nov 15, 2024Oct 15, 2024$1.55Quarterly
    Jun 20, 2024Aug 15, 2024Jul 15, 2024$1.55Quarterly
    Feb 15, 2024May 15, 2024Apr 15, 2024$1.55Quarterly
    Oct 27, 2023Feb 15, 2024Jan 16, 2024$1.55Quarterly

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about ABBV from trusted financial sources

      Related Companies

      Additional publicly traded companies similar to Abbvie (ABBV)
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      ⓒ 2025 Financhle. All Rights Reserved.